Approximately 70% of skin tumors have shrunk significantly

On August 12, 2021, Medivir announced that its topical histone deacetylase (HDAC) inhibitor remetinostat has obtained positive results in a phase 2 clinical trial for adjuvant treatment of patients with basal cell carcinoma (BCC)

BCC is a common skin cancer, and the current main treatment is surgical resection

Among the 33 tumors analyzed in the final analysis, the overall response rate (ORR) was 69.

▲Remetinostat molecular structure (picture source: PubChem)

Previously, a dose-escalation phase 2 trial of the drug in patients with mycosis fungal skin T-cell lymphoma (MF-CTCL) showed that the severity of skin lesions in patients decreased, with an objective response rate (ORR) of up to 40% At the highest dose, the severity of itching in 80% of patients was clinically significantly reduced

(The original text has been deleted)

Reference materials:

[1] Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research.

[2] Kilgour, JM, et, al.

[3] A New Type of Gel Shows Promise Against Common Type of Skin Cancer.